Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility and Prospective Randomized Study of Transarterial Chemoembolization using Irinotecan Bead in Combination with Second Line Chemotherapy in the Treatment of Patients with Unresectable Metastatic Colorectal Cancer (PARAGON)

Trial Profile

Feasibility and Prospective Randomized Study of Transarterial Chemoembolization using Irinotecan Bead in Combination with Second Line Chemotherapy in the Treatment of Patients with Unresectable Metastatic Colorectal Cancer (PARAGON)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2018

At a glance

  • Drugs Irinotecan (Primary) ; Irinotecan
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms PARAGON-I
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Aug 2010 The trial has received FDA approval for continuing into a randomised phase IIb trial, with results expected in 2012, as reported in a Biocompatibles International media release.
    • 03 Jul 2010 Promising results have been presented at the World Congress for Gastro-Intestinal Cancer, as reported in a Biocampatibles International media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top